Abhishek Basumallick, Founder & Chief Equity Advisor, Intelsense Capital, says “right now is a very good time to buy for probably the next two to three years. Right now means …
Mumbai: Concord Biotech’s strong foothold in the niche segment of manufacturing active pharmaceutical ingredients through fermentation along with its capacity expansion and planned launches are seen underpinning strong earnings growth …
“We expect yesterday’s underperformers to be winners of tomorrow, i.e. IT and Pharma. The valuations are very attractive from a long-term investment perspective despite short-term risks to earnings,” says Kedar …